ClinicalTrials.gg
RecruitingNCT07724457Updated Nov 17, 2026

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

A Phase 2/3 interventional study of Biospecimen Collection and Bone Marrow Biopsy in Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements and Refractory Burkitt Lymphoma, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Cancer Institute (NCI) · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
271
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies testing cyclophosphamide in Burkitt Lymphoma — 8 open to participants now, 17 under way, 3 of them phase 3. Cyclophosphamide · Burkitt Lymphoma.

Planned enrollment
8th of 79
271 · median 43
Started
2027
with 2 others
Phase 2/3
2 of 86
1 open now
Primary completion
2033-11
later than 16 of 16 live
Registered
84th of 86
by date
Lead sponsor
4 of 86
National Cancer Institute (NCI)

Among the 86 studies testing cyclophosphamide in Burkitt Lymphoma, this one is the 8th largest by planned enrollment of the 79 interventional ones that give a count, is one of 3 that started in 2027, is one of 2 in phase 2/3, reaches primary completion later than 16 of the 16 other live ones, and was the 84th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

8 of the 86 studies testing cyclophosphamide in Burkitt Lymphoma are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cyclophosphamide in Burkitt Lymphoma, or all of them as a file.
02

Study summary

This phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high grade (double hit) B- cell lymphomas that are newly diagnosed, that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Glofitamab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Obinutuzumab and rituximab are also monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make DNA and may kill cancer cells. Chemotherapy drugs, such as cytarabine and ifosfamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Giving glofitamab with standard of care chemotherapy may work well for the treatment of newly diagnosed, relapsed or refractory Burkitt and high grade (double hit) B- cell lymphomas.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare the progression free survival (PFS) of rituximab (R)-chemotherapy plus glofitamab versus R-chemotherapy alone in patients with newly diagnosed Burkitt lymphoma.

II. To compare the PFS of R-chemotherapy plus glofitamab versus R-chemotherapy alone in patients with newly diagnosed high grade (double hit) B-cell lymphoma with MYC and BCL2 rearrangements.

III. To determine the overall survival of obinutuzumab, rituximab, ifosfamide, carboplatin, etoposide (RICE), and glofitamab in patients with relapsed Burkitt lymphoma.

SECONDARY OBJECTIVES:

I. To compare the overall survival (OS) of R-chemotherapy plus glofitamab versus R-chemotherapy alone in patients with newly diagnosed Burkitt lymphoma, and patients with newly diagnosed high grade B-cell lymphoma with MYC and BCL2 rearrangements.

II. To compare the safety and tolerability of glofitamab combined with R-chemotherapy versus R-chemotherapy alone in patients with newly diagnosed Burkitt lymphoma, and patients with newly diagnosed high grade B-cell lymphoma with MYC and BCL2 rearrangements.

III. To determine the event free survival (EFS), complete response (CR) and overall response (OR) rates of obinutuzumab, RICE, and glofitamab in patients with relapsed Burkitt and high grade B-cell lymphoma.

IV. To assess how many patients undergo transplant or chimeric antigen receptor T-cell therapy (CART) after treatment with obinutuzumab, RICE, and glofitamab for relapsed Burkitt lymphoma.

EXPLORATORY OBJECTIVES:

I. To assess patient reported outcomes in patients with Burkitt and double hit lymphoma at study enrollment, during treatment and at the end of therapy.

II. To evaluate the completion rate of a lymphoma-specific patient assessment of life survey (PALS) for 7 patient directed questions on social determinants of health (SDH) and assess the impact of the survey collected data on outcomes for all enrolled patients.

OUTLINE: Patients with newly diagnosed Burkitt lymphoma are assigned to cohort 1, patients with double hit lymphoma are assigned to cohort 2, patients with relapsed or refractory Burkitt lymphoma or high grade lymphoma are assigned to cohort 3.

COHORT 1: Patients are randomized to 1 of 2 arms. Patients who received a single cycle of anthracycline containing chemotherapy will start treatment at cycle 2 22-36 days after cycle 1.

ARM 1: Patients receive either rituximab, cyclophosphamide, doxorubicin, vincristine and methotrexate (RCODOXM)/rituximab, ifosfamide, etoposide, cytarabine (RIVAC) or rituximab, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone (DA-REPOCH) treatment per the investigators choice. Patients over the age of 60 or with other co-morbidities are assigned to DA-REPOCH.

RCODOXM/RIVAC:

CYCLES 1 AND 3: Patients receive rituximab intravenously (IV) or rituxan hycela subcutaneously (SC) on day 1, cyclophosphamide IV on days 1 and 2, doxorubicin IV on day 1, vincristine IV on day 1 and 15 and methotrexate IV, over 2-4 hours on day 15.

CYCLES 2 AND 4: Patients receive rituximab IV or rituxan hycela SC on day 1, ifosfamide IV and etoposide IV on days 1-5, and cytarabine IV every 12 hours on days 1-2.

Patients without baseline central nervous system (CNS) disease also receive methotrexate intrathecally (IT) and cytarabine IT once per cycle for 4 treatments or methotrexate IT twice per cycle for 8 treatments or alternating methotrexate IT and cytarabine IT twice per cycle for 8 treatments.

Patients with baseline CNS disease also receive methotrexate IT and cytarabine IT twice weekly, methotrexate IT or alternating methotrexate IT and cytarabine IT until cerebrospinal fluid (CSF) clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles.

Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.

DA-REPOCH: Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone orally (PO) twice daily (BID) on days 1-5.

Patients without baseline CNS disease also receive methotrexate IT and cytarabine IT once per cycle for 4 treatments or methotrexate IT twice per cycle for 8 treatments or alternating methotrexate IT and cytarabine IT twice per cycle for 8 treatments.

Patients with baseline CNS disease also receive methotrexate IT and cytarabine IT twice weekly, methotrexate IT or alternating methotrexate IT and cytarabine IT until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles.

Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo positron emission tomography (PET), computed tomography (CT) scan, and/or magnetic resonance imaging (MRI) and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

ARM 2: Patients receive either RCODOXM/RIVAC or DA-REPOCH with glofitamab per the investigators choice. Patients over the age of 60 or with other co-morbidities are assigned to DA-REPOCH.

RCODOXM/RIVAC:

CYCLES 1 AND 3: Patients receive rituximab IV or rituxan hycela SC on day 1, cyclophosphamide IV on days 1 and 2, doxorubicin IV on day 1, vincristine IV on day 1 and 15 and methotrexate IV, over 2-4 hours on day 15. Patients also receive glofitamab IV, over 2-4 hours, on day 2 of cycle 3.

CYCLES 2 AND 4: Patients receive rituximab IV or rituxan hycela SC on day 1, ifosfamide IV and etoposide IV on days 1-5, and cytarabine IV every 12 hours on days 1-2. Patients also receive glofitamab IV, over 2-4 hours, on day 6 and 15 of cycle 2 and day 6, 22, 43 64 and 85 of cycle 4.

Patients without baseline CNS disease also receive methotrexate IT and cytarabine IT once per cycle for 4 treatments or methotrexate IT twice per cycle for 8 treatments or alternating methotrexate IT and cytarabine IT twice per cycle for 8 treatments. IT treatment can not be given on the same day as glofitamab.

Patients with baseline CNS disease also receive methotrexate IT and cytarabine IT twice weekly, methotrexate IT or alternating methotrexate IT and cytarabine IT until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. IT treatment can not be given on the same day as glofitamab.

Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.

DA-REPOCH: Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients also receive glofitamab IV, over 2-4 hours on day 6 and 15 of cycle 2, day 6 of cycle 3-5 and days 6, 22 and 43 of cycle 6.

Patients without baseline CNS disease also receive methotrexate IT and cytarabine IT once per cycle for 4 treatments or methotrexate IT twice per cycle for 8 treatments or alternating methotrexate IT and cytarabine IT twice per cycle for 8 treatments. IT treatment can not be given on the same day as glofitamab.

Patients with baseline CNS disease also receive methotrexate IT and cytarabine IT twice weekly, methotrexate IT or alternating methotrexate IT and cytarabine IT until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. IT treatment can not be given on the same day as glofitamab.

Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

COHORT 2: Patients are randomized to 1 of 2 arms.

ARM 3: Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5.

Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments.

Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles.

Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

ARM 4: Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients also receive glofitamab IV, over 2-4 hours, on day 6 and 15 of cycle 2, day 6 of cycle 3-5 and days 6, 22 and 43 of cycle 6.

Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. IT treatment can not be given on the same day as glofitamab.

Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. IT treatment can not be given on the same day as glofitamab.

Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

COHORT 3: Patients receive obinutuzumab IV on day 1 of cycle 1, rituximab IV or rituxan hycela SC on day 1 of cycles 2-4, ifosfamide IV continuously on day 2, carboplatin, over 1 hour, on day 2, etoposide IV, over 2 hours, on days 1-3 and glofitamab IV, over 2-4 hours, on day 8 and 15 of cycle 1, on day 4 of cycles 2-3 and day 4 and 22 of cycle 4.

Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. IT treatment can not be given on the same day as glofitamab.

Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. IT treatment can not be given on the same day as glofitamab.

Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Responding patients may come off study any time after cycle 3 to receive transplant or chimeric antigen receptor therapy.

Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years then every 6 months until 5 years.

03

Conditions studied

  • Recurrent Burkitt Lymphoma
  • Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
  • Refractory Burkitt Lymphoma
  • Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • BURKITT LYMPHOMA (BL) COHORT 1: confirmed Burkitt lymphoma by International Consensus Classification criteria. Patients with Burkitt lymphoma must have one or more of the following adverse risk factors at diagnosis:

    • Stage III or IV disease
    • Elevated lactate dehydrogenase (LDH) greater than institutional (ULN)
    • Tumor mass ≥ 7 cm
  • BL COHORT 1: No prior treatment except for pre-phase chemotherapy, pre-phase , or one cycle of chemotherapy as described below.

    • Pre-phase chemotherapy with corticosteroids or cyclophosphamide/prednisone is permitted prior to enrollment.
    • One cycle of prior chemotherapy (for example, cyclophosphamide, doxorubicin, vincristine and prednisone [CHOP], Polatuzumab-cyclophosphamide doxorubicin and prednisone [CHP], cyclophosphamide, vincristine, doxorubicin and methotrexate [CODOXM], or etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin [EPOCH] [with or without rituximab]) may be administered no more than 21 days prior to enrollment.
    • Patients enrolling on study after one cycle of prior anthracycline containing therapy will start the study therapy in cycle 2 and cycle 2 must occur no later than 22-36 days after the start of cycle 1. (If feasible, cycle 2 should start on day 22, but +14 days is permitted to permit recovery from toxicity in cycle 1)
  • BL COHORT 1: Age ≥ 18 years
  • BL COHORT 1: (ECOG) performance status ≤ 2. ECOG performance status of 3 is permitted if related to lymphoma
  • BL COHORT 1: (ANC) ≥ 1,000/mm\^3 (unless attributable to lymphoma)
  • BL COHORT 1: count ≥ 75,000/mm\^3 (unless attributable to lymphoma)
  • BL COHORT 1: Calculated (Calc.) ≥ 50 mL/min (unless attributable to lymphoma)
  • BL COHORT 1: (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN (unless attributable to lymphoma)
  • BL COHORT 1: Total ≤ 2.0 mg/dL (unless due to Gilbert's syndrome) (unless attributable to lymphoma)
  • BL COHORT 1: International normalization ratio () OR prothrombin time (PT) > 1.5 x institutional ULN (unless attributable to lymphoma)
  • BL COHORT 1: Partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) > 1.5 x institutional ULN (unless attributable to lymphoma)
  • BL COHORT 1: Not pregnant and not nursing, and willingness to remain abstinent or use because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. For women of only, a negative pregnancy test done less than or equal to 28 days prior to registration is required

    • Female participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment and for at least 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
    • Male participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for at least 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • BL COHORT 1: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen (i.e. anthracycline dosing that will exceed recommended lifetime maximum dosing) are eligible for this trial
  • BL COHORT 1: Patients with are eligible but must be on effective anti-retroviral therapy, with undetectable viral load within 6 months of enrollment
  • BL COHORT 1: Patients with a history of who are hepatitis B (HepB) surface antigen (Ag) positive and/or HepB core antibody (Ab) positive with undetectable Hep B viral load who start suppressive antiviral therapy prior to chemotherapy are eligible
  • BL COHORT 1: Patients with a history of infection that have been treated for hepatitis C virus (HCV) and have an undetectable HCV viral load are eligible
  • BL COHORT 1: No active ischemic heart disease or congestive heart failure, AND adequate cardiac function defined as of ≥ 45%
  • BL COHORT 1: Patients with CSF/ at diagnosis are eligible. Patients with parenchymal brain involvement at diagnosis are NOT eligible
  • BL COHORT 1: Patients requiring > 10 mg/day of prednisone or equivalent, for the treatment of conditions other than the control of lymphoma related symptoms, are NOT eligible
  • BL COHORT 1: Patients with major surgery within 4 weeks other than for diagnosis of lymphoma are NOT eligible
  • BL COHORT 1: Patients with known active infections, or reactivation of a latent infection (excluding fungal infections of nail bed, hepatitis B on suppressive therapy or treated hepatitis C) requiring hospitalization or treatment with IV antibiotics within 4 weeks of study treatment are NOT eligible
  • BL COHORT 1: Patients with a prior history of hemophagocytic lymphohistiocytosis (HLH) are NOT eligible
  • BL COHORT 1: Patients with a history of disease (including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Guillain-Barre syndrome, or multiple sclerosis) are NOT eligible.

However, patients with autoimmune related hypothyroidism on a stable dose of thyroid replacement hormone, patients with a history of lymphoma related immune thrombocytopenic purpura or hemolytic anemia, and patients with type 1 or type 2 diabetes on a stable insulin regimen are eligible to enroll. In addition, patients with eczema, lichen simplex chronicus, or vitiligo with dermatologic manifestations only may also enroll if the rash covers \< 10% of body surface area and the disease is well controlled and requires only topical corticosteroids.

Lastly, patients treated with prior immunotherapeutic agents with a history of any grade 3 events (except for grade 3 endocrinopathy managed with replacement therapy) or grade 1-2 events that did not resolve to baseline with treatment discontinuation are NOT eligible.

  • BL COHORT 1: Patients with a history of progressive multifocal leukoencephalopathy (PML) are NOT eligible
  • BL COHORT 1: Patients who have received live, attenuated vaccines within 4 weeks prior to cycle 1 day (D) 1 of study treatment are NOT eligible
  • DOUBLE HIT LYMPHOMA (DHL) COHORT 2: Histologically confirmed high grade/double hit B-cell lymphoma with MYC and BCL2 translocations by International Consensus Classification (ICC) or World Health Organization (WHO) criteria. Fluorescence in situ hybridization (FISH) For MYC and BCL2 translocations must be performed by the referring site and must be positive for translocations of BOTH MYC and BCL2. Patients found to have BCL6 translocations in addition to BOTH MYC and BCL2 (so called "triple hit lymphoma") are eligible
  • DHL COHORT 2: Stage II-IV disease per Lugano staging classification
  • DHL COHORT 2: No prior treatment except for pre-phase chemotherapy, pre-phase corticosteroids, or one cycle of chemotherapy as described below.

    • Pre-phase chemotherapy with corticosteroids or cyclophosphamide/prednisone is permitted prior to enrollment.
    • One cycle of prior chemotherapy (for example, CHOP, Polatuzumab-CHP, or EPOCH (with or without Rituximab)) may be administered no more than 21 days prior to enrollment.
    • Patients enrolling on study after one cycle of prior anthracycline containing therapy will start the study therapy in cycle 2 and cycle 2 must occur no later than 22-36 days after the start of cycle 1. (If feasible, cycle 2 should start on day 22, but +14 days is permitted to permit recovery from toxicity in cycle 1)
  • DHL COHORT 2: Age ≥ 18 years
  • DHL COHORT 2: ECOG performance status ≤ 2. ECOG performance status of 3 is permitted if related to lymphoma
  • DHL COHORT 2: Absolute neutrophil count (ANC) ≥ 1,000/mm\^ 3 (unless attributable to lymphoma)
  • DHL COHORT 2: Platelet Count ≥ 75,000/mm\^3 (unless attributable to lymphoma)
  • DHL COHORT 2: Calc. Creatinine Clearance ≥ 50 mL/min (unless attributable to lymphoma)
  • DHL COHORT 2: AST(SGOT)/ALT(SGPT) ≤ 3 x institutional ULN (unless attributable to lymphoma)
  • DHL COHORT 2: Total Bilirubin ≤ 2.0 mg/dL (unless due to Gilbert's Syndrome) (unless attributable to lymphoma)
  • DHL COHORT 2: INR OR PT > 1.5 x institutional ULN (unless attributable to lymphoma)
  • DHL COHORT 2: PTT or aPTT > 1.5 x institutional ULN (unless attributable to lymphoma)
  • DHL COHORT 2: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. For women of childbearing potential only, a negative pregnancy test done less than or equal to 28 days prior to registration is required

    • Female participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment and for at least 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
    • Male participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for at least 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • DHL COHORT 2: Patients with prior malignancy or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (i.e. anthracycline dosing that will exceed recommended lifetime maximum dosing) are eligible for this trial
  • DHL COHORT 2: Patients with HIV are eligible but must be on effective anti-retroviral therapy, with undetectable viral load within 6 months of enrollment
  • DHL COHORT 2: Patients with a history of hepatitis B who are HepB surface Ag positive and/or HepB core Ab positive with undetectable Hep B viral load who start suppressive antiviral therapy prior to chemotherapy are eligible
  • DHL COHORT 2: Patients with a history of hepatitis C infection that have been treated for HCV and have an undetectable HCV viral load are eligible
  • DHL COHORT 2: No active ischemic heart disease or congestive heart failure, AND adequate cardiac function defined as ejection fraction of ≥ 45%
  • DHL COHORT 2: Patients with CSF/leptomeningeal involvement at diagnosis are eligible. Patients with parenchymal brain involvement at diagnosis are NOT eligible
  • DHL COHORT 2: Corticosteroid use: Patients requiring > 10 mg/day of prednisone or equivalent, for the treatment of conditions other than the control of lymphoma related symptoms, are NOT eligible
  • DHL COHORT 2: Patients with major surgery within 4 weeks other than for diagnosis of lymphoma are NOT eligible
  • DHL COHORT 2: Patients with known active infections, or reactivation of a latent infection (excluding fungal infections of nail bed, hepatitis B on suppressive therapy, or treated hepatitis C) requiring hospitalization or treatment with IV antibiotics within 4 weeks of study treatment are NOT eligible
  • DHL COHORT 2: Patients with a prior history of HLH are NOT eligible
  • DHL COHORT 2: Patients with a history of autoimmune disease (including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Guillain-Barre syndrome, or multiple sclerosis) are NOT eligible.

However, patients with autoimmune related hypothyroidism on a stable dose of thyroid replacement hormone, patients with a history of lymphoma related immune thrombocytopenic purpura or hemolytic anemia, and patients with type 1 or type 2 diabetes on a stable insulin regimen are eligible to enroll. In addition, patients with eczema, lichen simplex chronicus, or vitiligo with dermatologic manifestations only may also enroll if the rash covers \< 10% of body surface area and the disease is well controlled and requires only topical corticosteroids.

Lastly, patients treated with prior immunotherapeutic agents with a history of any grade 3 events (except for grade 3 endocrinopathy managed with replacement therapy) or grade 1-2 events that did not resolve to baseline with treatment discontinuation are NOT eligible

  • DHL COHORT 2: Patients with a history of PML are NOT eligible
  • DHL COHORT 2: Patients who have received live, attenuated vaccines within 4 weeks prior to cycle 1 D1 of study treatment are NOT eligible
  • BL AND HGL COHORT 3: Histologically confirmed Burkitt lymphoma by International Consensus Classification criteria
  • RELAPSED BL AND HGL COHORT 3: Patients must have relapsed or refractory disease after at least one prior treatment with chemotherapy or chemoimmunotherapy.

    • Prior radiotherapy in addition or in conjunction with prior chemotherapy is permitted.
    • Patients who have previously received a bispecific antibody (BsAb) are NOT eligible. However, patients enrolled to the standard arms on cohorts 1 and 2 of this trial who did not receive glofitamab and have relapsed or refractory disease are eligible to enroll on cohort 3.
    • Prior treatment with systemic immunotherapeutic agents including antibody drug conjugates, radio-immunoconjugates, or immune/cytokine direct therapy must have occurred within 3 weeks or five half-lives of the drug, whichever is shorter
  • RELAPSED BL AND HGL COHORT 3: Age ≥ 18 years
  • RELAPSED BL AND HGL COHORT 3: ECOG Performance Status ≤ 2. ECOG performance status of 3 is permitted if related to lymphoma
  • RELAPSED BL AND HGL COHORT 3: Absolute Neutrophil Count (ANC) ≥ 1,000/mm\^3 (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: Platelet Count ≥ 75,000/mm\^3 (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: Calc. Creatinine Clearance ≥ 50 mL/min (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: AST(SGOT)/ALT(SGPT) ≤ 3 x institutional ULN (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: Total bilirubin ≤ 2.0 mg/dL (unless due to Gilbert's Syndrome) (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: INR OR PT > 1.5 x institutional ULN (unless due to Gilbert's Syndrome) (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: PTT or aPTT > 1.5 x institutional ULN (unless due to Gilbert's Syndrome) (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. For women of childbearing potential only, a negative pregnancy test done less than or equal to 28 days prior to registration is required

    • Female participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment and for at least 18 months after obinutuzumab, 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
    • Male participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for at least 6 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • RELAPSED BL AND HGL COHORT 3: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (i.e. anthracycline dosing that will exceed recommended lifetime maximum dosing) are eligible for this trial
  • RELAPSED BL AND HGL COHORT 3: Patients with HIV are eligible but must be on effective anti-retroviral therapy, with undetectable viral load within 6 months of enrollment
  • RELAPSED BL AND HGL COHORT 3: Patients with a history of hepatitis B who are HepB surface Ag positive and/or HepB core Ab positive with undetectable Hep B viral load who are taking suppressive antiviral therapy are eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with a history of hepatitis C infection that have been treated for HCV and have an undetectable HCV viral load are eligible
  • RELAPSED BL AND HGL COHORT 3: No active ischemic heart disease or congestive heart failure, AND adequate cardiac function defined as ejection fraction of ≥ 45%
  • RELAPSED BL AND HGL COHORT 3: Patients with CSF/leptomeningeal involvement at diagnosis are eligible. Patients with parenchymal brain involvement at diagnosis are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Corticosteroid use: Patients requiring > 10 mg/day of prednisone or equivalent, for the treatment of conditions other than the control of lymphoma related symptoms, are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with major surgery within 4 weeks other than for diagnosis of lymphoma are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with known active infections, or reactivation of a latent infection (excluding fungal infections of nail bed, hepatitis B on suppressive therapy, or treated hepatitis C) requiring hospitalization or treatment with IV antibiotics within 4 weeks of study treatment are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with a prior history of HLH are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with a history of autoimmune disease (includi
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
271 participants (estimated)

Study arms

  • Experimental
    Cohort 1 arm 2 RCODOXM/RIVAC or DA-REPOCH and glofitamab)

    See Detailed Description

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Doxorubicin · Drug: Etoposide · Biological: Glofitamab · Drug: Ifosfamide · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Drug: Methotrexate · Procedure: Positron Emission Tomography · Drug: Prednisone · Biological: Rituximab · Biological: Rituximab and Hyaluronidase Human · Other: Survey Administration · Drug: Vincristine

  • Experimental
    Cohort 1, arm 1 RCODOXM/RIVAC or DA-REPOCH)

    See Detailed Description.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Doxorubicin · Drug: Etoposide · Drug: Ifosfamide · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Drug: Methotrexate · Procedure: Positron Emission Tomography · Drug: Prednisone · Biological: Rituximab · Biological: Rituximab and Hyaluronidase Human · Other: Survey Administration · Drug: Vincristine

  • Experimental
    Cohort 2 arm 3 (DA-REPOCH)

    Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Doxorubicin · Drug: Etoposide · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Drug: Methotrexate · Procedure: Positron Emission Tomography · Drug: Prednisone · Biological: Rituximab · Biological: Rituximab and Hyaluronidase Human · Other: Survey Administration · Drug: Vincristine

  • Experimental
    Cohort 2 arm 4 (DA-REPOCH and glofitamab)

    Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients also receive glofitamab IV, over 2-4 hours, on day 6 and 15 of cycle 2, day 6 of cycle 3-5 and days 6, 22 and 43 of cycle 6. Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. IT treatment can not be given on the same day as glofitamab. Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. IT treatment can not be given on the same day as glofitamab. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Doxorubicin · Drug: Etoposide · Biological: Glofitamab · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Drug: Methotrexate · Procedure: Positron Emission Tomography · Biological: Rituximab · Biological: Rituximab and Hyaluronidase Human · Other: Survey Administration · Drug: Vincristine

  • Experimental
    Cohort 3 (RICE and glofitamab)

    See Detailed Description

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Drug: Carboplatin · Procedure: Computed Tomography · Drug: Cytarabine · Drug: Etoposide · Biological: Glofitamab · Drug: Ifosfamide · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Drug: Methotrexate · Biological: Obinutuzumab · Procedure: Positron Emission Tomography · Biological: Rituximab · Biological: Rituximab and Hyaluronidase Human · Other: Survey Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood and/or cerebrospinal fluid collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Frindovyx, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719

  • Given IV or IT

    Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453

  • Given IV

    Also known as: Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin

  • Given IV

    Also known as: Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213

  • BiologicalGlofitamab

    Given IV

    Also known as: Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, Columvi, Glofitamab-gxbm, RO 7082859, RO-7082859, RO7082859

  • Given IV

    Also known as: Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942

  • ProcedureLumbar Puncture

    Undergo lumbar puncture

    Also known as: LP, Spinal Tap

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given IV or IT

    Also known as: Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039

  • BiologicalObinutuzumab

    Given IV

    Also known as: Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759

  • ProcedurePositron Emission Tomography

    Undergo PET scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • Given PO

    Also known as: .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone

  • BiologicalRituximab

    Given IV

    Also known as: ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima

  • BiologicalRituximab and Hyaluronidase Human

    Drug page: Rituximab and Hyaluronidase HumanStudies of Rituximab and Hyaluronidase HumanRituximab and Hyaluronidase Human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given SC

    Also known as: Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human

  • OtherSurvey Administration

    Ancillary studies

  • Given IV

    Also known as: LCR, Leurocristine, VCR, Vincrystine

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) (cohort 1) (phase II)

    The median PFS will be summarized by sex with corresponding 95% confidence intervals.

    Time frame: from randomization to the time of documented disease progression or death due to any cause

  2. PFS (cohort 1) (phase III)

    PFS defined as from randomization to the time of documented disease progression or death due to any cause. Will be as estimated using the methods of Kaplan and Meier. The median PFS and the 24-month PFS rates will be summarized by sex with corresponding 95% confidence intervals.

    Time frame: At 24 months

  3. PFS (cohort 2) (phase II)

    The median PFS will be summarized by sex with corresponding 95% confidence intervals.

    Time frame: From randomization to the time of documented disease progression or death due to any cause, up to 5 years

  4. PFS (cohort 2) (phase III)

    PFS defined as from randomization to the time of documented disease progression or death due to any cause. Will be as estimated using the methods of Kaplan and Meier. The median PFS and the 24-month PFS rates will be summarized by sex with corresponding 95% confidence intervals.

    Time frame: At 24 months

  5. Overall survival (cohort 3)

    Time frame: At 12 months after start of treatment

Secondary outcomes

  1. Overall survival (OS)

    Will be evaluated between the treatment arms for each of the cohorts. Kaplan Meier methods will be used to estimate key aspects of the OS distributions for each of the treatment arms, and logrank tests will be used to compare these distributions between arms.

    Time frame: From randomization to the time of death due to any cause, up to 5 years

  2. Event free survival (EFS)

    Will be evaluated between the treatment arms for each of the cohorts. Kaplan Meier methods will be used to estimate key aspects of the EFS distributions for each of the treatment arms, and logrank tests will be used to compare these distributions between arms.

    Time frame: From randomization date until the earlier of non-protocol lymphoma therapy, disease progression or death from any cause, up to 5 years

  3. Overall response rate (ORR)

    Defined as the number of patients achieving complete or partial response according to either the computed tomography(CT)-based or positron emission tomography (PET)-CT-based Lugano criteria, divided by the number of evaluable patients. will be estimated by treatment arm, and a 95% binomial confidence interval for the estimated ORR will be provided. Will be evaluated between the treatment arms for each of the cohorts.

    Time frame: Up to 5 years

  4. Complete response rate

    Defined as the number of patients achieving complete response according to either the CT-based or PET-CT-based Lugano criteria, divided by the number of evaluable patients. The CR rate will be estimated by treatment arm, and a 95% binomial confidence interval for the estimated CR rate will be provided.

    Time frame: Up to 5 years

  5. Transplant or chimeric antigen receptor t-cell (CAR-T) rate (cohort 3)

    Defined as the number of Cohort 3 patients who undergo transplant or CAR-T after treatment with Rituximab-Ifosfamide-Carboplatin-Etoposide plus Glofitamab, divided by the number of Cohort 3 patients who receive at least one dose of protocol therapy. The transplant or CAR-T rate will be estimated and the corresponding 95% binomial confidence interval will be provided.

    Time frame: Up to 5 years

  6. Incidence of adverse events (AEs)

    Will be summarized per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5 and Patient Reported Outcome-CTCAE, and where toxicities will be defined as adverse events that are deemed to be at least possibly treatment-related. The maximum grade for each type of treatment-related AE will be recorded for each patient, and the frequency of each will be summarized by treatment arm. Frequency tables and graphical evaluations of AEs and treatment-related AEs will be summarized and evaluated to assess if there are any patterns or differences in the rates or types of AEs.

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jul 2027; primary completion for Nov 2033, 75 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jul 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 24, 2026
StartEst.
Jul 27, 2027was Oct 2026
Primary completionEst.
Nov 1, 2033
CompletionEst.
Nov 1, 2033
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
1 site added — first site in United States
Show site
  • Alliance for Clinical Trials in Oncology · Chicago, United States
Nov 17, 2026
Start date
Oct 30, 2026→Jul 27, 2027
Nov 17, 2026
Eligibility
7 criteria edited, 6 added, 4 removed
What changed in the criteria
  • EditedBL COHORT 1: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, forFor women of childbearing potential only, a negative pregnancy test done ≤less than or equal to 28 days prior to registration is required
  • AddedFemale participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
  • AddedMale participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • EditedBL COHORT 1: Patients with a prior history of hemophagocytic lymphohistocytosislymphohistiocytosis (HLH) are NOT eligible
  • EditedDHL COHORT 2: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, forFor women of childbearing potential only, a negative pregnancy test done ≤less than or equal to 28 days prior to registration is required
  • AddedFemale participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
  • AddedMale participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • EditedDHL COHORT 2: Patients with a history of hepatitis B who are HepB surface Ag positive and/or HepB core Ab positive with undetectable Hep B viral load who who start suppressive antiviral therapy prior to chemotherapy are eligible
  • EditedPatients who have previously received a bispecific antibody (BsAb) are NOT eligible. However, patients enrolled to the standard arms on cohorts 1 and 2 of this trial who did not receive glofitimabglofitamab and have relapsed or refractory disease are eligible to enroll on cohort 3.
  • EditedRELAPSED BL AND HGL COHORT 3: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, forFor women of childbearing potential only, a negative pregnancy test done ≤less than or equal to 28 days prior to registration is required
  • AddedFemale participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 18 months after obinutuzumab, 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
  • AddedMale participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • RemovedRELAPSED BL AND HGL COHORT 3: Patients with a history of autoimmune disease (including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Guillain-Barre syndrome, or multiple sclerosis) are NOT eligible.
  • RemovedHowever, patients with autoimmune related hypothyroidism on a stable dose of thyroid replacement hormone, patients with a history of lymphoma related immune thrombocytopenic purpura or hemolytic anemia, and patients with type 1 diabetes on a stable insulin regimen are eligible to enroll. In addition, patients with eczema, lichen simplex chronicus, or vitiligo with dermatologic manifestations only may also enroll if the rash covers < 10% of body surface area and the disease is well controlled and requires only topical corticosteroids.
  • RemovedLastly, patients treated with prior immunotherapeutic agents with a history of any grade 3 events (except for grade 3 endocrinopathy managed with replacement therapy) or grade 1-2 events that did not resolve to baseline with treatment discontinuation are NOT eligible
  • EditedRELAPSED BL AND HGL COHORT 3: Patients with a history of PML are NOT eligibleautoimmune disease (includi
  • RemovedRELAPSED BL AND HGL COHORT 3: Patients who have received live, attenuated vaccines within 4 weeks prior to cycle 1 D1 of study treatment are NOT eligible
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Alliance for Clinical Trials in Oncology · Chicago, United States
    Start date Oct 30, 2026→Jul 27, 2027
    Eligibility 7 criteria edited, 6 added, 4 removed
    What changed in the criteria
    • EditedBL COHORT 1: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, forFor women of childbearing potential only, a negative pregnancy test done ≤less than or equal to 28 days prior to registration is required
    • AddedFemale participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
    • AddedMale participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
    • EditedBL COHORT 1: Patients with a prior history of hemophagocytic lymphohistocytosislymphohistiocytosis (HLH) are NOT eligible
    • EditedDHL COHORT 2: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, forFor women of childbearing potential only, a negative pregnancy test done ≤less than or equal to 28 days prior to registration is required
    • AddedFemale participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
    • AddedMale participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
    • EditedDHL COHORT 2: Patients with a history of hepatitis B who are HepB surface Ag positive and/or HepB core Ab positive with undetectable Hep B viral load who who start suppressive antiviral therapy prior to chemotherapy are eligible
    • EditedPatients who have previously received a bispecific antibody (BsAb) are NOT eligible. However, patients enrolled to the standard arms on cohorts 1 and 2 of this trial who did not receive glofitimabglofitamab and have relapsed or refractory disease are eligible to enroll on cohort 3.
    • EditedRELAPSED BL AND HGL COHORT 3: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, forFor women of childbearing potential only, a negative pregnancy test done ≤less than or equal to 28 days prior to registration is required
    • AddedFemale participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 18 months after obinutuzumab, 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
    • AddedMale participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
    • RemovedRELAPSED BL AND HGL COHORT 3: Patients with a history of autoimmune disease (including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Guillain-Barre syndrome, or multiple sclerosis) are NOT eligible.
    • RemovedHowever, patients with autoimmune related hypothyroidism on a stable dose of thyroid replacement hormone, patients with a history of lymphoma related immune thrombocytopenic purpura or hemolytic anemia, and patients with type 1 diabetes on a stable insulin regimen are eligible to enroll. In addition, patients with eczema, lichen simplex chronicus, or vitiligo with dermatologic manifestations only may also enroll if the rash covers < 10% of body surface area and the disease is well controlled and requires only topical corticosteroids.
    • RemovedLastly, patients treated with prior immunotherapeutic agents with a history of any grade 3 events (except for grade 3 endocrinopathy managed with replacement therapy) or grade 1-2 events that did not resolve to baseline with treatment discontinuation are NOT eligible
    • EditedRELAPSED BL AND HGL COHORT 3: Patients with a history of PML are NOT eligibleautoimmune disease (includi
    • RemovedRELAPSED BL AND HGL COHORT 3: Patients who have received live, attenuated vaccines within 4 weeks prior to cycle 1 D1 of study treatment are NOT eligible
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07724457
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Jul 27, 2027 (estimated)
Primary completion
Nov 1, 2033 (estimated)
Completion
Nov 1, 2033 (estimated)
Last update
Nov 17, 2026

Study contacts

Kristie A Blum
principal investigator · Alliance for Clinical Trials in Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Doxorubicin · Glofitamab · Ifosfamide · Prednisone · Vincristine

Start the discussion